Cargando…
Is D2 Lymphadenectomy Alone Suitable for Gastric Cancer With Bulky N2 and/or Para-Aortic Lymph Node Metastases After Preoperative Chemotherapy?
BACKGROUND: For gastric cancer (GC) with extensive lymph node metastasis (bulky N2 and/or para-aortic lymph node metastases), there is no standard therapy worldwide. In Japan, preoperative chemotherapy (PCT) followed by D2 gastrectomy plus para-aortic lymph node dissection (PAND) is considered the s...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444230/ https://www.ncbi.nlm.nih.gov/pubmed/34540676 http://dx.doi.org/10.3389/fonc.2021.709617 |
_version_ | 1784568446697078784 |
---|---|
author | Xu, Wei Liu, Wentao Wang, Lingquan He, Changyu Lu, Sheng Ni, Zhentian Hua, Zichen Zhu, Zhenglun Sah, Birendra Kumar Yang, Zhongyin Zheng, Yanan Feng, Runhua Li, Chen Yao, Xuexin Chen, Mingmin Yan, Chao Yan, Min Zhu, Zhenggang |
author_facet | Xu, Wei Liu, Wentao Wang, Lingquan He, Changyu Lu, Sheng Ni, Zhentian Hua, Zichen Zhu, Zhenglun Sah, Birendra Kumar Yang, Zhongyin Zheng, Yanan Feng, Runhua Li, Chen Yao, Xuexin Chen, Mingmin Yan, Chao Yan, Min Zhu, Zhenggang |
author_sort | Xu, Wei |
collection | PubMed |
description | BACKGROUND: For gastric cancer (GC) with extensive lymph node metastasis (bulky N2 and/or para-aortic lymph node metastases), there is no standard therapy worldwide. In Japan, preoperative chemotherapy (PCT) followed by D2 gastrectomy plus para-aortic lymph node dissection (PAND) is considered the standard treatment for these patients. However, in China, the standard operation for GC patients with only bulky N2 metastases was D2 gastrectomy. Besides, after PCT, whether doing PAND improves survival or not is debatable for GC patients with para-aortic lymph node (PAN) metastases. Therefore, we conducted this study to investigate whether D2 lymphadenectomy alone is suitable for these patients after PCT. METHODS: We retrospectively collected data on patients from our electronic medical record system. GC patients with bulky N2 and/or PAN metastases who underwent D2 lymphadenectomy alone after PCT were enrolled. The survival outcomes and chemotherapy responses were analyzed and compared with the results of the JCOG0405 study. RESULTS: From May 2009 to December 2017, a total of 83 patients met all eligibility criteria and were enrolled. The median survival duration for all patients was 40.0 months. The 3-year and 5-year OS rates for all patients were 50.3% and 45.6%, respectively. For patients with only bulky N2 metastasis, the 3-year and 5-year OS rates were 77.1% and 71.6%, respectively, which were similar to the results of the JCOG0405 study (82.7% and 73.4%). For patients with only PAN metastases, the 3-year and 5-year OS rates were 50.0% and 50.0%, respectively, which seemed to be lower than those of the JCOG0405 study (64.3% and 57.1%). For patients with bulky N2 and PAN metastases, the 3-year and 5-year OS rates were 7.4% and 0.0%, respectively, which were lower than those of the JCOG0405 study (20.0% and 20.0%). CONCLUSION: The results of our study suggest that D2 lymphadenectomy alone is suitable for GC patients with only bulky N2 metastasis after PCT. However, D2 lymphadenectomy alone perhaps is not suitable for patients with bulky N2 and PAN metastases after PCT. |
format | Online Article Text |
id | pubmed-8444230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84442302021-09-17 Is D2 Lymphadenectomy Alone Suitable for Gastric Cancer With Bulky N2 and/or Para-Aortic Lymph Node Metastases After Preoperative Chemotherapy? Xu, Wei Liu, Wentao Wang, Lingquan He, Changyu Lu, Sheng Ni, Zhentian Hua, Zichen Zhu, Zhenglun Sah, Birendra Kumar Yang, Zhongyin Zheng, Yanan Feng, Runhua Li, Chen Yao, Xuexin Chen, Mingmin Yan, Chao Yan, Min Zhu, Zhenggang Front Oncol Oncology BACKGROUND: For gastric cancer (GC) with extensive lymph node metastasis (bulky N2 and/or para-aortic lymph node metastases), there is no standard therapy worldwide. In Japan, preoperative chemotherapy (PCT) followed by D2 gastrectomy plus para-aortic lymph node dissection (PAND) is considered the standard treatment for these patients. However, in China, the standard operation for GC patients with only bulky N2 metastases was D2 gastrectomy. Besides, after PCT, whether doing PAND improves survival or not is debatable for GC patients with para-aortic lymph node (PAN) metastases. Therefore, we conducted this study to investigate whether D2 lymphadenectomy alone is suitable for these patients after PCT. METHODS: We retrospectively collected data on patients from our electronic medical record system. GC patients with bulky N2 and/or PAN metastases who underwent D2 lymphadenectomy alone after PCT were enrolled. The survival outcomes and chemotherapy responses were analyzed and compared with the results of the JCOG0405 study. RESULTS: From May 2009 to December 2017, a total of 83 patients met all eligibility criteria and were enrolled. The median survival duration for all patients was 40.0 months. The 3-year and 5-year OS rates for all patients were 50.3% and 45.6%, respectively. For patients with only bulky N2 metastasis, the 3-year and 5-year OS rates were 77.1% and 71.6%, respectively, which were similar to the results of the JCOG0405 study (82.7% and 73.4%). For patients with only PAN metastases, the 3-year and 5-year OS rates were 50.0% and 50.0%, respectively, which seemed to be lower than those of the JCOG0405 study (64.3% and 57.1%). For patients with bulky N2 and PAN metastases, the 3-year and 5-year OS rates were 7.4% and 0.0%, respectively, which were lower than those of the JCOG0405 study (20.0% and 20.0%). CONCLUSION: The results of our study suggest that D2 lymphadenectomy alone is suitable for GC patients with only bulky N2 metastasis after PCT. However, D2 lymphadenectomy alone perhaps is not suitable for patients with bulky N2 and PAN metastases after PCT. Frontiers Media S.A. 2021-09-02 /pmc/articles/PMC8444230/ /pubmed/34540676 http://dx.doi.org/10.3389/fonc.2021.709617 Text en Copyright © 2021 Xu, Liu, Wang, He, Lu, Ni, Hua, Zhu, Sah, Yang, Zheng, Feng, Li, Yao, Chen, Yan, Yan and Zhu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xu, Wei Liu, Wentao Wang, Lingquan He, Changyu Lu, Sheng Ni, Zhentian Hua, Zichen Zhu, Zhenglun Sah, Birendra Kumar Yang, Zhongyin Zheng, Yanan Feng, Runhua Li, Chen Yao, Xuexin Chen, Mingmin Yan, Chao Yan, Min Zhu, Zhenggang Is D2 Lymphadenectomy Alone Suitable for Gastric Cancer With Bulky N2 and/or Para-Aortic Lymph Node Metastases After Preoperative Chemotherapy? |
title | Is D2 Lymphadenectomy Alone Suitable for Gastric Cancer With Bulky N2 and/or Para-Aortic Lymph Node Metastases After Preoperative Chemotherapy? |
title_full | Is D2 Lymphadenectomy Alone Suitable for Gastric Cancer With Bulky N2 and/or Para-Aortic Lymph Node Metastases After Preoperative Chemotherapy? |
title_fullStr | Is D2 Lymphadenectomy Alone Suitable for Gastric Cancer With Bulky N2 and/or Para-Aortic Lymph Node Metastases After Preoperative Chemotherapy? |
title_full_unstemmed | Is D2 Lymphadenectomy Alone Suitable for Gastric Cancer With Bulky N2 and/or Para-Aortic Lymph Node Metastases After Preoperative Chemotherapy? |
title_short | Is D2 Lymphadenectomy Alone Suitable for Gastric Cancer With Bulky N2 and/or Para-Aortic Lymph Node Metastases After Preoperative Chemotherapy? |
title_sort | is d2 lymphadenectomy alone suitable for gastric cancer with bulky n2 and/or para-aortic lymph node metastases after preoperative chemotherapy? |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444230/ https://www.ncbi.nlm.nih.gov/pubmed/34540676 http://dx.doi.org/10.3389/fonc.2021.709617 |
work_keys_str_mv | AT xuwei isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT liuwentao isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT wanglingquan isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT hechangyu isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT lusheng isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT nizhentian isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT huazichen isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT zhuzhenglun isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT sahbirendrakumar isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT yangzhongyin isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT zhengyanan isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT fengrunhua isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT lichen isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT yaoxuexin isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT chenmingmin isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT yanchao isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT yanmin isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy AT zhuzhenggang isd2lymphadenectomyalonesuitableforgastriccancerwithbulkyn2andorparaaorticlymphnodemetastasesafterpreoperativechemotherapy |